Industries > Pharma > Global Hypertension Drugs Market 2019-2029

Global Hypertension Drugs Market 2019-2029

Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs)

PUBLISHED: 31 July 2019
PAGES: 145
PRODUCT CODE: PHA0457
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0457 Categories: , Tag:

The global hypertension drugs market is estimated to have reached $24.7bn in 2018 and is expected to reach the market value of $19.3bn by 2029 with a CAGR of -2.3% from 2019 to 2029.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 146-page report you will receive 118 charts– all unavailable elsewhere.

The 146-page report provides clear detailed insight into the hypertension drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Hypertension Drugs Market forecasts from 2019-2029

• Global Pulmonary Arterial Hypertension (PAH) Market forecasts from 2019-2029

• Revenue forecasts for the Hypertension Drugs by Class of Drug from 2019-2029:
• Angiotensin II Receptor Blockers (ARBs): further broken down into revenue forecast of Atacand, Avapro, Diovan, Cozaar, Benicar, Entresto, Micardis, Azilva, Candesartan
• Angiotensin-converting Enzyme (ACE) Inhibitor: further broken down into revenue forecast of Tritace
• Beta-Blockers: further broken down into revenue forecast of Seloken/Toprol-XL, Coreg CR, Concor
• Calcium Channel Blockers (CCBs): further broken down into revenue forecast of Norvasc, Plendil, Adalat, Amlodin
• Diuretics
• Fixed-dose Combinations (FDC): further broken down into revenue forecast of Azor, Tribenzor, Exforge, Tekturna HCT, others

• Revenue forecasts for the leading PAH drugs from 2019-2029:
• Tacleer
• Uptravi
• Opsumit
• Letairis
• Adcirca
• Revatio
• Adempas
• Veletri
• Oremitram
• Tyvaso
• Remodulin

• Revenue forecasts for the Hypertension Drugs by Regional and National Market from 2019-2029:
• U.S.
• Canada
• Mexico
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Russia
• Japan
• China
• India
• Rest of Asia
• Brazil
• South Africa
• Rest of the World

Global Hypertension Drugs Market 2019-2029

• Profiles and discussion on the leading companies of the hypertension drugs market:
• Actelion
• AstraZeneca
• Boehringer Ingelheim GmbH
• Daiichi Sankyo
• Johnson & Johnson Company
• Merck & Co.
• Novartis
• Pfizer
• Sanofi Aventis
• United Therapeutics

• Analysis of the Drivers, Restraints, Opportunities and Porter’s Five Forces analysis of the global hypertension drugs market

• Key Questions Answered by this Report:
• How is the Hypertension Drugs market evolving?
• What is driving and restraining the Hypertension Drugs market dynamics?
• How will each of the submarkets grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each of the Hypertension Drugs submarkets develop from 2019 to 2029?
• What will be the main driver for the overall market from 2019-2029?
• How will political and regulatory factors influence the regional markets and submarkets?
• How will the market shares of the national markets change by 2029 and which geographical region will lead the market in 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry sector evolve during the period between 2019 and 2029?

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Hypertension Drugs Market. You find data, trends and predictions.

Buy our report today Global Hypertension Drugs Market 2019-2029: Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs).

Visiongain is a trading partner with the US Federal Government
CCR Ref number KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Hypertension Drugs Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Hypertension Drugs Market 2019-2029


Latest Pharma news

“Global Cell Therapy Technologies market set to grow to $23bn by 2024” says new Visiongain report

Cell therapy technologies are used across various research areas including gene therapy, cancer vaccines, regenerative medicine, biologics and others. Increasing global disease burdens and the need for more personalised & precision medicine has led to massive growth in the cell technology market, which is likely to increase over the next decade.

19 February 2020

READ

“Global Asthma & COPD market set to grow to $49 bn by 2025” says new Visiongain report

The Asthma and COPD market has the potential to bring several blockbuster drugs to the marketplace due to the increasingly segmented sub-groups of patients.

17 February 2020

READ

“Global Rheumatoid Arthritis Drugs market estimated to grow at a CAGR of 0.6% in the second half of the forecast period” says Visiongain report

Another factor driving the growth in the market is the discovery of new molecules that are involved in the disease process, and hence, new strategies for treating the disease.

17 February 2020

READ

Visiongain assesses that the Contract Research Organisations (CROs) market will generate revenues of $38.0 billion in 2020

Global clinical research organizations market was valued at $34.9 billion in 2019 and is projected to grow at a CAGR of 9.5% during the forecast period 2020-2030.

12 February 2020

READ

Categories

Category